^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    COM701

    i
    Other names: COM701, CGEN-15029, COM701/PVRIG, COM 701, COM-701, CGEN15029, CGEN 15029
    Company:
    Compugen
    Drug class:
    PVRIG inhibitor
    Related drugs:
    5ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Compugen Ltd | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date • Platinum sensitive
    |
    COM701
    7ms
    CPG-02-101: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=110, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • COM701 • COM902
    8ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Compugen Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive
    |
    COM701
    9ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Compugen Ltd
    New P1/2 trial
    |
    COM701
    over1year
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=48, Completed, Compugen Ltd | Active, not recruiting --> Completed | N=100 --> 48
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    over1year
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=121, Completed, Compugen Ltd | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701
    almost2years
    COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=110, Recruiting, Compugen Ltd | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • COM701 • COM902
    almost2years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Trial completion date: Dec 2023 --> Aug 2024 | Trial primary completion date: Dec 2023 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    almost2years
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Compugen Ltd | Phase classification: P1a/1b --> P1 | Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Feb 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701
    almost3years
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1a/1b, N=140, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2022 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • HER-2 negative • BRCA mutation
    |
    Opdivo (nivolumab) • COM701
    almost3years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Active, not recruiting, Compugen Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    over3years
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Compugen Ltd | Trial primary completion date: Aug 2022 --> Jan 2023
    Trial primary completion date • Combination therapy
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)